COVID-19 Pipeline Summary

DelveInsight’s, “COVID-19 Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

COVID-19 Disease Understanding

COVID-19 Overview

COVID-19 is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus. COVID-19 has had a catastrophic effect on the world, resulting in more than 6 million deaths worldwide. Like other RNA viruses, SARS-CoV adapts with genetic evolution and developing mutations. This results in mutant variants that may have different characteristics than their ancestral strains.

The symptoms of COVID-19, caused by SARS-CoV-2, vary widely in severity, ranging from asymptomatic infection to severe respiratory illness. The most common symptoms include fever, dry cough, fatigue, and shortness of breath, often accompanied by sore throat, headache, and muscle aches. Many individuals also experience loss of taste or smell, which became a distinguishing feature of the disease. In some cases, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur. Severe cases can progress to pneumonia, chest pain, confusion, and difficulty breathing, potentially leading to acute respiratory distress and multi-organ complications. 

The pathophysiology of COVID-19 is driven by infection with SARS-CoV-2, a structurally complex virus containing spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The spike protein plays a central role in disease initiation, where its receptor-binding domain attaches to ACE2 receptors expressed in the respiratory epithelium and multiple organs. Viral entry is facilitated by host proteases such as TMPRSS2, enabling membrane fusion and intracellular replication. In the early phase, viral replication causes direct cytopathic damage to infected tissues, particularly in the lungs. As the disease progresses, an exaggerated immune response is triggered, characterized by activation of immune cells and release of pro-inflammatory cytokines including IL-6, TNF-α, and interferon-γ. In severe cases, this leads to a “cytokine storm,” resulting in widespread systemic inflammation and tissue injury. 

The etiology of COVID-19 is linked to infection with SARS-CoV-2, a betacoronavirus closely related to SARS-CoV and MERS-CoV. Genomic studies suggest a zoonotic origin, with bats as the primary reservoir and possible intermediate hosts such as pangolins before transmission to humans. The virus spreads mainly through respiratory droplets and aerosols during close contact, with minor contributions from contaminated surfaces and other routes. Mutations in the viral genome have led to multiple variants, such as Alpha, Delta, and Omicron, which enhance transmissibility and influence disease dynamics. 

The diagnosis of COVID-19 primarily relies on detection of SARS-CoV-2 RNA using real-time PCR from nasopharyngeal or related specimens, which remains the gold standard due to its high specificity. Antigen tests provide faster results but are less sensitive, while serological tests are not recommended for diagnosing acute infection. Laboratory evaluations in hospitalized patients include blood counts, metabolic panels, inflammatory markers, and D-dimer levels to assess disease severity and guide management. Imaging modalities such as chest X-ray and CT scans may reveal characteristic findings like bilateral ground-glass opacities, although they are not definitive for diagnosis.
Treatment strategies depend on disease stage, targeting viral replication in early infection and immune dysregulation in later stages. Antiviral therapies such as Remdesivir, Nirmatrelvir (with ritonavir), and Molnupiravir are used in early or mild-to-moderate disease, particularly in high-risk patients. In hospitalized or severe cases, corticosteroids like Dexamethasone and immunomodulators such as Tocilizumab or baricitinib are recommended to control inflammation.

"COVID-19 Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the COVID-19 pipeline landscape is provided which includes the disease overview and COVID-19 treatment guidelines. The assessment part of the report embraces, in depth COVID-19 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, COVID-19 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest COVID-19 pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

COVID-19 Pipeline Report Highlights

The COVID-19 companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches to treat/improve COVID-19.

COVID-19 Emerging Drugs Analysis

This COVID-19 segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

COVID-19 Emerging Drugs

VYD-2311: Invivyd, Inc.

VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd’s proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.

Ibuzatrelvir: Pfizer 

Ibuzatrelvir (PF-07817883) is an investigational, second-generation oral SARS-CoV-2 main protease inhibitor developed by Pfizer to treat COVID-19. It acts as a single agent without requiring ritonavir boosting, offering a potential advantage in reducing drug-drug interactions, and has shown significant viral reduction in Phase 2 trials. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.

N-803: ImmunityBio, Inc.

N-803 is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

ENTVAX002: Entos Pharmaceuticals Inc.

ENTVAX002 (also known as Covigenix VAX-002) is an investigational, next-generation COVID-19 booster vaccine developed by Entos Pharmaceuticals in partnership with Aegis Life. It is a plasmid DNA (pDNA) vaccine specifically engineered to combat emerging SARS-CoV-2 Omicron variants, utilizing the company's proprietary Fusogenix proteo-lipid vehicle (PLV) platform for delivery. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

ALG-097558: Aligos Therapeutics

ALG-097558 is a potent ritonavir-free pan-coronavirus protease inhibitor (PI). In preclinical studies, ALG‑097558 has been shown to be at least 6-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants. It has demonstrated broad pan-coronavirus activity, including against SARS and MERS. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

RBM001: Rock BioMedical, Inc.

RBM001 is a low-sugar, broad-spectrum COVID-19 protein vaccine developed by Rock BioMedical, a Taiwan-based biotech company. The vaccine is designed to address rapidly mutating viruses by removing glycan shields from the spike protein, exposing highly conserved, less-mutable areas to the immune system, thus providing wider protection against various strains. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

MDX2301: OPKO Health, Inc.

MDX2301 is a multispecific antibody therapy for the prevention of COVID-19 designed to neutralize diverse SARS-CoV-2 variants. The ModeX multispecific antibody format enables the rational combination of multiple binding sites in a single antibody, aiming to broaden coverage against current and future viral variants while enabling potent neutralization and the potential for enhanced therapeutic efficacy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

PA-001: PeptiDream Inc.

PA-001, a peptide-based inhibitor targeting the S2 domain of the SARS-CoV-2 spike protein, a protein essential for coronavirus entry into human cells. The S2 region is highly conserved across variants and subvariants, and PA-001 demonstrated potent activity against all major variants from Wuhan to Omicron BA.5. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

Further product details are provided in the report……..

COVID-19 Drug Therapeutic Assessment

This COVID-19 segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:

Major COVID-19 Players in COVID-19  

• There are approx. 180+ key companies which are developing the therapies for COVID-19. The companies which have their COVID-19 drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

COVID-19 Clinical Trial Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

COVID-19 Drug Route of Administration

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

COVID-19 Product Molecule Type

COVID-19 Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

COVID-19 Product Type

COVID-19 Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

COVID-19 Clinical Trial Activities

The COVID-19 Pipeline report provides insights into COVID-19 Clinical Trials within phase II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs. 

COVID-19 Pipeline Development Activities

The COVID-19 Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.

COVID-19 Pipeline Report Insights

• COVID-19 Pipeline Analysis
• COVID-19 Therapeutic Assessment
• COVID-19 Market Unmet Needs
• Impact of COVID-19 Drugs

COVID-19 Pipeline Report Assessment

• COVID-19 Pipeline Product Profiles
• COVID-19 Therapeutic Assessment
• COVID-19 Pipeline Assessment
•  COVID-19 Inactive drugs assessment
• COVID-19 Market Unmet Needs

Discover actionable insights into the COVID-19 market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The COVID-19 Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many COVID-19companies are developing COVID-19 drugs?
• How many COVID-19 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for COVID-19 and their status?
• What are the key designations that have been granted to the emerging drugs?

COVID-19 Key Companies

• Invivyd, Inc.
• Pfizer
• ImmunityBio, Inc.
• Entos Pharmaceuticals Inc.
• Rock BioMedical, Inc.
• OPKO Health, Inc.
• Lumen Bioscience, Inc.
• PeptiDream Inc.
• AstraZeneca
• HDT Bio
• Sanofi
• Imunon
• KBio Inc
• Enanta Pharmaceuticals, Inc
• Inflammx Therapeutics Inc
• Vaxart Inc
• BioVie Inc.
• AIM ImmunoTech Inc.
• CyanVac LLC
• Vasomune Therapeutics, Inc.
• Shionogi & Co., Ltd.
• GeneOne Life Science, Inc.
• Berlin Cures GmbH
• Resverlogix Corp
• Cocrystal Pharma, Inc.
• Coeptis Therapeutics Holdings, Inc.
• Immorna Biotherapeutics, Inc.
• VBI Vaccines Inc.
• Oneness Biotech Co., Ltd.
• Senhwa Biosciences, Inc.

COVID-19 Key Products

• V-2311
• Ibuzatrelvir
• N-803
• ENTVAX002
• RBM001
• MDX2301
• LMN-301
• PA-001
• AZD5156
• HDT-301
• SP0287
• IMNN-101
• KB20V
• EDP-235
• Tonabersat
• VXA-CoV2-3.1
• Rintatolimod
• NE3107
• CVXGA
• AV-001
• S-268019
• GLS-1027
• BC-007
• Apabetalone
• CDI-988
• DVX-201
• JCXH-221
• VBI-2902
• SNS-812
• CX-4945